Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

2022-502940-10-00 Protocol MS201924_0003 Human pharmacology (Phase I) - Other Ended

Start 23 Feb 2024 · End 14 Apr 2026 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol MS201924_0003

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 12
Countries 1
Sites 2

Advanced Solid Tumors

Key facts

Sponsor
Merck Healthcare KGaA
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
23 Feb 2024 → 14 Apr 2026
Decision date (initial)
2024-02-01
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065147 Malignant solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Merck Healthcare KGaA

Sponsor organisation
Merck Healthcare KGaA
Address
Frankfurter Strasse 250
City
Darmstadt
Postcode
64293
Country
Germany

Scientific contact point

Organisation
Merck Healthcare KGaA
Contact name
Communication Center Merck KGaA

Public contact point

Organisation
Merck Healthcare KGaA
Contact name
Communication Center Merck KGaA

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Hungary Ended 12 2
Rest of world 0

Investigational sites

Hungary

2 sites · Ended
Central Hospital Of Northern Pest Military Hospital
Oncology, Podmaniczky Utca 109, 1062, Budapest VI
Pharmaceutical Research Associates Magyarorszag
N/A, Rottenbiller Utca 13, 1077, Budapest

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Hungary 2024-02-23 2026-04-14 2024-03-25 2025-09-15

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-06 Hungary Acceptable
2024-01-30
2024-02-01
2 SUBSTANTIAL MODIFICATION SM-1 2024-04-10 Hungary Acceptable
2024-05-21
2024-05-23
3 SUBSTANTIAL MODIFICATION SM-2 2024-09-13 Hungary Acceptable
2024-11-21
2024-11-22
4 NON SUBSTANTIAL MODIFICATION NSM-1 2025-01-29 Hungary Acceptable
2024-11-21
2025-01-29
5 SUBSTANTIAL MODIFICATION SM-3 2025-04-01 Hungary Acceptable 2025-05-13
6 SUBSTANTIAL MODIFICATION SM-5 2025-06-18 Hungary Acceptable
2025-07-25
2025-07-29
7 NON SUBSTANTIAL MODIFICATION NSM-2 2026-01-29 Hungary Acceptable
2025-07-25
2026-01-29